Ono Pharmaceutical Co., Ltd. (4528.T) JPX

2,158.00

-58.5(-2.64%)

Updated at June 03 03:23PM

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Gyo Sagara	Chief Executive Officer & Chairman of the Board	142M	1958
Toshihiro Tsujinaka	Corp Sr Ex Off, Chief CMC & Prod, Dig Tech, Glob Qual, Bus Trans Dept Off, Bus Des/Chief Off and Dir	78M	1964
Toichi Takino	President, Chief Operating Officer & Representative Director	102M	1968
Hiroyuki Takahashi	Director of Oncology Business Division	0	N/A
Satoshi Takahagi	Senior Director of EHS Promotion & Corporate Officer	0	N/A
Hiromu Habashita	Corporate Officer, Senior Vice President, Discovery & Research	0	N/A
Masayuki Tanigawa	Corporate Officer, Executive VP of Business Strategy & VP of License	0	N/A
Tatsuya Okamoto	Corporate Officer & Executive Director of Clinical Development, Oncology Clinical Development Div.	0	N/A
Shinji Takai	Corporate Officer & Head of Medical Affairs	0	N/A
Thomas Lechner	Vice President of Medical Affairs	0	N/A
Masaki Ito	Corporate Executive Officer and Div. Director of Corporate Strategy, Planning & Bus. Management Div.	0	N/A
Takehiro Yamada	Corporate Officer & Head of Risk and Compliance Management Department	0	N/A
Akira Takada	Corporate Executive Officer & Executive Director of CMC & Production	0	N/A

Name

Title

Pay

Year Born

Gyo Sagara

Chief Executive Officer & Chairman of the Board

142M

1958

Toshihiro Tsujinaka

Corp Sr Ex Off, Chief CMC & Prod, Dig Tech, Glob Qual, Bus Trans Dept Off, Bus Des/Chief Off and Dir

78M

1964

Toichi Takino

President, Chief Operating Officer & Representative Director

102M

1968

Hiroyuki Takahashi

Director of Oncology Business Division

N/A

Satoshi Takahagi

Senior Director of EHS Promotion & Corporate Officer

N/A

Hiromu Habashita

Corporate Officer, Senior Vice President, Discovery & Research

N/A

Masayuki Tanigawa

Corporate Officer, Executive VP of Business Strategy & VP of License

N/A

Tatsuya Okamoto

Corporate Officer & Executive Director of Clinical Development, Oncology Clinical Development Div.

N/A

Shinji Takai

Corporate Officer & Head of Medical Affairs

N/A

Thomas Lechner

Vice President of Medical Affairs

N/A

Masaki Ito

Corporate Executive Officer and Div. Director of Corporate Strategy, Planning & Bus. Management Div.

N/A

Takehiro Yamada

Corporate Officer & Head of Risk and Compliance Management Department

N/A

Akira Takada

Corporate Executive Officer & Executive Director of CMC & Production

N/A

Description

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.